Investigation of the effect of artemisinin and Dermaneh and Afsantinin the treatment of coronavirus COVID-19 virus

INTERVENTION: Intervention 1: Intervention group: The intervention group will receive two Dermaneh capsules of artemisinin 100 mg, two capsules (each containing 5oo mg Dermaneh ) and two Dermaneh capsules (each containing 500 mg Afsantin) daily. Patients will be given daily capsules in packs containing 70capsules and we ask patients to take five capsules daily for 14 days. Intervention 2: Control group: The control group will receive placebo capsules daily. Patients will be given capsules in packs containing 84 capsules and we ask patients to take six capsules daily for 14 days. CONDITION: U07.1 COVID‐19. ; COVID‐19, virus identified PRIMARY OUTCOME: C‐reactive protein. Timepoint: At the beginning of the study (before the intervention) , 7 days after the intervention, 14 days after intervention. Method of measurement: Venous blood test. Lymphocytes. Timepoint: At the beginning of the study (before the intervention) and 14 days after intervention. Method of measurement: Venous blood test. Respiratory Rate. Timepoint: At the beginning of the study (before the intervention) and14 days after intervention. Method of measurement: Respiratory Count. Oxygen saturation. Timepoint: At the beginning (before the intervention) and 14 days after intervention. Method of measurement: Pulse Oximeter. SECONDARY OUTCOME: Headache. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Anorexia. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Cough. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Muscle pain. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Sore throat. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Fatigue. Timepoint: At the beginning of the study (before the intervention)and 14 days after the intervention. Method of measurement: Questionnaire. INCLUSION CRITERIA: Patients with signing Informed Consent Age 18‐65 years old Positive CRP test for SARS‐CoV‐2 virus or characteristic signs on a CT scan of the chest with mild to moderate clinical manifestations according to the National Early Warning Score (NEWS) (mild: 1‐4 / moderate: 5‐6)